Can Selumetinib/Coseyou completely cure café-au-lait spots?
Although selumetinib (Selumetinib) has shown a clear effect in NF1-related plexiformneurofibromatosis, its effect on Café-au-lait spots (Café-au-lait spots) currently has no evidence to support "complete cure" or "permanent elimination." Café-au-lait spots are one of the most common skin manifestations of NF1 and are caused by changes in skin melanocyte activity. Selumetinib targets the MEK signaling pathway and has a significant impact on the proliferation of plexiform neurofibroma cells, but has limited improvement in epidermal melanin pigmentation. The disease mechanisms of the two are not exactly the same.
Data show that during the use of selumetinib, the café-au-lait spots of a small number of patients may become slightly lighter, but this change varies greatly among different individuals and has not yet formed a stable pattern that can be adopted by medical guidelines. Therefore, selumetinib is not considered a formal drug for the treatment of café-au-lait spots. Its main clinical value is still focused on reducing the size of plexiform neurofibromas, improving pain, reducing compression symptoms, and improving the quality of daily life.
Café-au-lait spots themselves are not malignant lesions, nor will they automatically transform into tumors. Their main concern is their appearance. The current management of café-au-lait spots in the international medical community is still dominated by dermatological laser treatment, but even laser is difficult to completely remove, and there are recurring cases. Therefore, it is unrealistic to completely eliminate café-au-lait spots as a treatment goal, and selumetinib cannot fulfill this role.
For For children with NF1 and their families, it is more important to distinguish the difference between "appearance" and "pathological plexiform neurofibroma". At present, the main significance of Selumetinib is to help control the growth of tumors, thereby reducing pain, improving limb function, and avoiding more important health problems such as compression of nerves or organs.
Reference materials:https://www.koselugo.com
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)